

Applicant: Don Fishbein
Serial No.: 10/799,197
Filed: March 12, 2004
Page 2 of 12 of Amendment and SIDS

Amendments to the Claims:

Pursuant to 37 C.F.R. §1.121(c), this listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims

1-29. (Canceled)

30. (Currently Amended) A method of promoting weight gain after weight loss resulting from post-burn catabolism in a patient which comprises administering to the patient a therapeutically effective amount of oxandrolone effective for promoting weight gain in said patient wherein the weight gained is maintained at five weeks after discontinuation of oxandrolone administration.

31. (Previously Presented) A method according to claim 30 wherein the amount of oxandrolone administered is about 1-100 mg per day.

32. (Previously Presented) A method according to claim 31 wherein the amount of oxandrolone administered is about 80 mg per day.

33. (Previously Presented) A method according to claim 31 wherein the amount of oxandrolone administered is about 20 mg per day.

Applicant: Don Fishbein
Serial No.: 10/799,197
Filed: March 12, 2004
Page 3 of 12 of Amendment and SIDS

34. (Previously Presented) A method according to claim 31 wherein the amount of oxandrolone administered is about 10 mg per day.
35. (Previously Presented) A method according to claim 31 wherein the amount of oxandrolone administered is about 2.5 mg per day.
36. (Previously Presented) A method according to claim 30 wherein the oxandrolone is administered orally.
37. (Previously Presented) A method according to claim 30 wherein the oxandrolone is administered topically.
38. (Previously Presented) A method according to claim 30 wherein the oxandrolone is administered by injection.
39. (Previously Presented) A method according to claim 30 wherein the oxandrolone is in a solid dosage form.
40. (Previously Presented) A method according to claim 30 wherein the oxandrolone is in a liquid dosage form.
41. (Previously Presented) A method according to claim 30 wherein the oxandrolone is in a sustained-release formulation.
42. (Previously Presented) A method according to claim 30 wherein the oxandrolone is 17 α -methyl-17 β -hydroxy-2-oxa-5 α -androstan-3-one.

Applicant: Don Fishbein
Serial No.: 10/799,197
Filed: March 12, 2004
Page 4 of 12 of Amendment and SIDS

43. (Previously Presented) A method according to claim 30 further comprising administering a protein supplement.
44. (Previously Presented) A method according to claim 30 wherein the weight gained comprises lean body mass.
45. (Previously Presented) A method according to claim 30 wherein the weight gained is maintained.
46. (Canceled).
47. (Currently Amended) A method according to claim 43 ~~30~~, wherein the weight gained per unit time in the patient is double the weight gained by a patient suffering weight loss resulting from post-burn catabolism receiving the protein supplement but not the oxandrolone.